Bausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
Follow BLCO
Alert me
Bausch + Lomb Corporation 10-K filed Feb 18, 2026
What changed
Item 1, Business, against the 10-K filed Feb 19, 2025: 13 added · 5 removed · 44 modified; 15 with only figures updated
-
Modified
Bausch + Lomb understands that BHC continues to believe that completing the Separation, which may include the
transfermonetization of all or a portion of BHC’sremaining direct or indirect equityownership interest in Bausch + Lombto its shareholders (, the sale of the Company (a “DistributionSale Transaction”), themonetizationtransfer of all or a portion of BHC’sownershipremaining direct or indirect equity interest in Bausch + Lomb, the sale ofto its shareholders (theCompany (a“Sale TransactionDistribution”), or a combination thereof, makes strategic sense and that BHC continues to evaluate all relevant factors and considerations related to completing the Separation, including those factors described in BHC’s public filings. The Distribution is subject to the achievement of targeted debt leverage ratios and the completion of the Separation is subject to the receipt of any applicable shareholder and other necessary approvals and other factors and is subject to various risk factors. See Item 1A. “Risk Factors” of this Form 10-K for additional information on the risks associated with the Separation. There can be no assurance that the Separation will be consummated, the form any such consummated Separation would take or that a Distribution or Sale Transaction will occur as part of that Separation or that even if consummated, we will realize the anticipated benefits from the Separation.